Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Voyager Therapeutics (VYGR) over the last 9 years, with Jun 2025 value amounting to -$49,000.

  • Voyager Therapeutics' Gains from Investment Securities rose 78.41% to -$49,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$303,000, marking a year-over-year increase of 16.07%. This contributed to the annual value of $8.8 million for FY2024, which is 18.52% up from last year.
  • Voyager Therapeutics' Gains from Investment Securities amounted to -$49,000 in Q2 2025, which was down 63.33% from -$30,000 recorded in Q1 2025.
  • Over the past 5 years, Voyager Therapeutics' Gains from Investment Securities peaked at $8.9 million during Q1 2024, and registered a low of -$2.8 million during Q4 2022.
  • Over the past 3 years, Voyager Therapeutics' median Gains from Investment Securities value was -$33,500 (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Voyager Therapeutics' Gains from Investment Securities crashed by 3,619.12% in 2021 and then soared by 566.22% in 2022.
  • Voyager Therapeutics' Gains from Investment Securities (Quarterly) stood at -$2.5 million in 2021, then fell by 12.50% to -$2.8 million in 2022, then surged by 98.77% to -$35,000 in 2023, then increased by 8.57% to -$32,000 in 2024, then skyrocketed by 78.41% to -$49,000 in 2025.
  • Its Gains from Investment Securities was -$49,000 in Q2 2025, compared to -$30,000 in Q1 2025 and -$32,000 in Q4 2024.